Systemic treatment of oesophageal cancer

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 3, 2004, Pages 249-254

  Richel, Dirk J ^a   Vervenne, Walter L ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant; Chemotherapy; Metastatic; Neoadjuvant; Oesophageal cancer

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; TAXANE DERIVATIVE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG ACTIVITY; ESOPHAGUS CANCER; HUMAN; META ANALYSIS; METASTASIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; SURGICAL MORTALITY; SURVIVAL; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 1642396646     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200403000-00002     Document Type: Review

References (36)

1. Devesa SS, Blot WJ, Fraumeni JFJ. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049-2053.
2. Arnott SJ, Duncan W, Gignoux M, Girling DJ, Hansen HS, Launois B, et al. Preoperative radiotherapy for esophageal carcinoma (Cochrane Review). In: Cochrane Library Issue 3, Oxford; 2002.
3. Zieren HU, Muller JM, Jacobi CA, Pichlmaier H, Muller RP, Staar S. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg 1995; 19:444-449.
4. Fok M, Sham JS, Choy D, Cheng SW, Wong J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993; 113:138-147.
5. Teniere P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. Surg Gynecol Obstet 1991; 173:123-130.
6. Pouliquen X, Levard H, Hay JM, McGee KC, Fingerhut A, Langlois-Zantin O. 5-Fluorouracil and cisplatin in therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. Ann Surg 1996; 223:127-133.
7. Ando N, Iizuka T, Kakegawa T, Isono K, Watanabe H, Ide H, et al. A randomized trial with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus. J Thorac Cardiovasc Surg 1997; 114:205-209.
8. Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobson A, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992; 16:1104-1109.
9. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinber S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988; 96:242-248.
10. Schlag P. Randomized study of preoperative chemotherapy in squamous cell cancer of the esophagus. Arch Surg 1992; 127:1446-1450.
11. Maipang T, Vasinanukorn P, Petpichetchian C, Chamroonkul S, Geater A, Chansawwaang S, et al. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol 1994; 56:191-197.
12. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114:210-217.
13. Kok TC, Lanschot van JJ, Siersema PD, Overhagen HV, Tilanus HW. Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: final report of a phase III randomized controlled trial. Proc Am Soc Clin Oncol 1997; 16:984.
14. Kelsen DP, Ginsberg R, Payak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339:1979-1984. Randomized study without evidence for survival advantage for neoadjuvant chemotherapy.
15. Ancona E, Ruol A, Santi S, Merigliamo S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomised, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91:2165-2174.
16. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727-1733. Large randomized study, demonstrating a significant increase in survival in patients treated with neoadjuvant chemotherapy.
17. Malthaner R, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 1: CD001556, 2001. This Cochrane analysis demonstrated a small survival advantage for neoadjuvant chemotherapy.
18. Urschel JD, Vasan H, Blewett CJ. A meta-analytis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 183:274-279. This meta-analysis did not demonstrate a survival benefit for neoadjuvant chemotherapy.
19. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994; 41:391-393.
20. Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Edouin D, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994; 73:1779-1784.
21. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Marition G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337:161-167.
22. Urba SG, Orringer MB, Turrisi A, Lannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19:305-313. In this study comparing neoadjuvant concurrent Chemoradiotherapy with surgery alone no difference in survival between the two study arms was demonstrated.
23. Walsh TN, Noonan N, Hollywood D, Kelly A, Stat C, Keeling N, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462-467. This study included only patients with adenocarcinoma; a significant survival benefit in the chemoradiotherapy arm was shown. The OK mortality was considerable (10%).
24. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593-1598.
25. Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15:277-284.
26. Wobbes T, Baron B, Paillot B, Jacob JH, Haegele P, Gignoux M, et al. Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus. Eur J Cancer 2001; 37:470-477.
27. Schmid EU, Alberts AS, Greef F, Terblanche APS, Schoeman L, Burger W, et al. The value of radiotherapy or chemotherapy after intubation for advanced esophageal carcinoma - a randomized trial. Radioth Oncol 1993; 28:27-30.
28. Levard H, Pouliquen X, Hay JM, Fingerhut A, Langois-Zantain O, Huguier M, et al. 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous carcinoma: a multicentre randomised controlled trial. The French Association for Surgical Research. Eur J Surg 1998; 164:849-857.
29. Manell A, Becker PJ, Melissas J, Diamantes T. Intubation v dilatation plus bleomycin in the treatment of advanced oesophageal cancer: the results of a prospective randomized trial. S Afr J Surg 1986; 24:15-19.
30. Bleiberg H, Conroy T, Paillot B, Lavace AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33:1216.
31. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophageal cancer. J Clin Oncol 1997; 15:261.
32. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophageal cancer. J Clin Oncol 2002; 20:1996-2004.
33. Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002; 86:669-673.
34. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Huntingt) 2002; 16(6 suppl 6):89-96.
35. Enzinger PC, Ilson DH. Irinotecan in esophageal cancer. Review. Oncology (Huntingt) 2000; 14(12 suppl 14):26-30.
36. 18FDG-PET and the response of oesophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003; 21:428-432.